Search Results

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to eight new employees.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.

Soleno Therapeutics, Inc. announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update, and reported financial results for the first quarter ended March 31, 2024.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.